#osteoarthritis

3 stories

Clinical Trials April 3, 2026 · View digest

Retatrutide Achieves 28.7% Weight Loss and Knee Pain Reduction in TRIUMPH-4 Phase 3 Trial

Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist retatrutide demonstrated up to 28.7% weight loss along with significant knee pain reductions in obesity patients with osteoarthritis. Seven additional Phase 3 trials expected to report throughout 2026.

Clinical Trials March 31, 2026 · View digest

TRIUMPH-4 Phase 3 Data Highlights Retatrutide's Significant Weight Loss and Knee Pain Reduction

Detailed Phase 3 results for Eli Lilly's triple-agonist (GLP-1/GIP/glucagon) showed significant weight loss alongside improved pain and physical function in obesity-related knee osteoarthritis. Seven additional Phase 3 trials underway.

Clinical Trials March 26, 2026 · View digest

Retatrutide Achieves Record 28.7% Weight Loss in Phase 3 TRIUMPH-4 Trial

Eli Lilly's triple-agonist achieved record weight loss at the highest dose with substantial reductions in knee osteoarthritis pain. Seven more Phase 3 trials expected in 2026.